Literature DB >> 12966616

Case report: severe central nervous system involvement in juvenile dermatomyositis.

Elisabeth F Elst1, Sylvia S M Kamphuis, Berent J Prakken, Nicolas M Wulffraat, Janjaap van der Net, A C Boudewyn Peters, Wietse Kuis.   

Abstract

We present 3 patients with juvenile dermatomyositis (JDM) and severe central nervous system (CNS) complications. All patients had at least 4 positive criteria of Bohan and Peter, which confirmed a definite diagnosis of JDM. They were all male, and had a relatively high creatinine kinase value at admission (1532-4260 U/l). Besides, progressive proximal muscle weakness and rash, one patient presented with rapid irreversible decline of vision. Ophthalmologic examination showed active vasculitis of the retina. After 2 weeks of treatment with immunosuppressive drugs and being in improved, relatively stable clinical condition, all 3 patients developed generalized tonic-clonic convulsions. Other causes of the neurological symptoms could be excluded. In all 3 patients, the course of JDM was fatal. The clinical symptoms and further investigations in our patients show CNS involvement in JDM. Although rarely reported, CNS vasculopathy can be a serious and life-threatening complication of JDM.

Entities:  

Mesh:

Year:  2003        PMID: 12966616

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

Review 1.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 2.  Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis.

Authors:  Theonymfi Doudouliaki; Charalampia Papadopoulou; Claire T Deakin
Journal:  Curr Rheumatol Rep       Date:  2021-03-08       Impact factor: 4.592

Review 3.  Treatment of Calcinosis in Juvenile Dermatomyositis.

Authors:  Ovgu Kul Cinar; Charalampia Papadopoulou; Clarissa A Pilkington
Journal:  Curr Rheumatol Rep       Date:  2021-02-08       Impact factor: 4.592

Review 4.  Paediatric idiopathic inflammatory muscle disease: recognition and management.

Authors:  Clarissa A Pilkington; Lucy R Wedderburn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Childhood Cerebral Vasculitis : A Multidisciplinary Approach.

Authors:  Neetika Gupta; Shivaprakash B Hiremath; Richard I Aviv; Nagwa Wilson
Journal:  Clin Neuroradiol       Date:  2022-06-24       Impact factor: 3.156

6.  Multiple symptoms of higher brain dysfunction caused by Marchiafava-Bignami disease in a patient with dermatomyositis.

Authors:  Kanako Furukawa; Etsuko Maeshima; Shinichiro Maeshima; Masakazu Ichinose
Journal:  Rheumatol Int       Date:  2009-10-22       Impact factor: 2.631

7.  Hemophagocytic lymphohistiocytosis with leukoencephalopathy in a patient with dermatomyositis accompanied with peripheral T-cell lymphoma: a case report.

Authors:  Satoru Teshigawara; Yoshinori Katada; Yuichi Maeda; Maiko Yoshimura; Eriko Kudo-Tanaka; Soichiro Tsuji; Yoshinori Harada; Masato Matsushita; Shiro Ohshima; Kotaro Watanabe; Takahiro Kumode; Yoshihiko Hoshida; Yukihiko Saeki
Journal:  J Med Case Rep       Date:  2016-08-02

8.  Aggressive immunosuppressive treatment of Susac's syndrome in an adolescent: using treatment of dermatomyositis as a model.

Authors:  Robert M Rennebohm; Martin Lubow; Jerome Rusin; Lisa Martin; Deborah M Grzybowski; John O Susac
Journal:  Pediatr Rheumatol Online J       Date:  2008-01-29       Impact factor: 3.054

9.  Encephalopathic Susac's Syndrome associated with livedo racemosa in a young woman before the completion of family planning.

Authors:  Maik Engeholm; Beate Leo-Kottler; Hansjörg Rempp; Tobias Lindig; Holger Lerche; Ilka Kleffner; Melanie Henes; Marcel Dihné
Journal:  BMC Neurol       Date:  2013-11-25       Impact factor: 2.474

Review 10.  The Vasculopathy of Juvenile Dermatomyositis.

Authors:  Charalampia Papadopoulou; Liza J McCann
Journal:  Front Pediatr       Date:  2018-10-09       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.